Marek Salagierski2, Maciej Salagierski1, Waldemar Różański2, Anna Salagierska-Barwińska3
- 1I Klinika Urologii Uniwersytetu Medycznego w Łodzi
2II Klinika Urologii Uniwersytetu Medycznego w Łodzi
3Zakład Radiologii i Diagnostyki Obrazowej Uniwersytetu Medycznego w Łodzi
kidney percutaneous radiofrequency ablation treatment tumour
- The aim of the study.
The aim of this study was to describe our experience with percutaneous ultrasound guided radiofrequency
- ablation of kidney tumours.
- Material and method.
From July 2002 to August 2008, 103 radiofrequency ablations (RFA) in patients with kidney tumours were
- performed. The average tumour size was 35 mm (range, 17-59 mm) with the mean age of 67 years (range, 18-84 years). Most of
- the RFA candidates had contraindications to surgery. Needle biopsy was not done on a regular basis and RFA was performed based
- on radiographic findings. The average ablation time was between 10 and 15 minutes. The procedure was performed under conscious
- sedation with local anaesthesia. Treatment efficacy was assessed by computed tomography. The absence of contrast enhancement
- was considered to be a successful treatment.
The average follow up was 30 months (range, 6-72 months). In 98 tumours (94%) total absence of contrast enhancement
- was obtained after the initial RFA and in 5 tumours (6%) after the second ablation session. There were no complications following
- 99 procedures (96%). In four procedures minor complications were observed. In one patient during the follow up a metastasis to a
- homolateral adrenal gland was discovered and one patient died of a pancreatic cancer.
RFA is a minimally invasive and safe treatment option in kidney tumours management. Despite the promising results
- the long-term follow-up is necessary to establish the oncological durability of RFA.